Vanda Pharmaceuticals (VNDA) EBT Margin (2010 - 2026)

Vanda Pharmaceuticals has disclosed EBT Margin across 17 years of filings, most recently posting 93.63% for Q1 2026.

• EBT Margin for Q1 2026 came in at 93.63%, down 1896.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 68.74% (down 4111.0% YoY), and the FY2025 annual result was 64.16%, down 5263.0% from the prior year.
• EBT Margin came in at 93.63% for Q1 2026 at Vanda Pharmaceuticals, down from 66.42% in the prior quarter.
• In the past five years, EBT Margin ranged from a high of 14.91% in Q4 2022 to a low of 93.63% in Q1 2026.
• The 5-year median for EBT Margin is 10.93% (2024), against an average of 21.8%.
• Across the five-year window, EBT Margin soared 2141 bps in 2023 and sank 6485 bps in 2025, its largest moves.
• Vanda Pharmaceuticals' EBT Margin stood at 14.91% in 2022, then tumbled by 125 bps to 3.67% in 2023, then sank by 233 bps to 12.22% in 2024, then tumbled by 444 bps to 66.42% in 2025, then slumped by 41 bps to 93.63% in 2026.
• The last three EBT Margin figures came in at 93.63% (Q1 2026), 66.42% (Q4 2025), and 50.46% (Q3 2025), per Business Quant data.